TY  - INPR
UR  - http://dx.doi.org/10.1007/s00330-024-10970-7
TI  - Measuring repeatability of dynamic contrast-enhanced MRI biomarkers improves evaluation of biological response to radiotherapy in lung cancer
KW  - Biomarkers; 
Magnetic resonance imaging; 
Lung neoplasms; 
Statistics
ID  - discovery10196058
SN  - 0938-7994
N1  - This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article?s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article?s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
JF  - European Radiology
EP  - 10
AV  - public
N2  - Objectives:
To measure dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) biomarker repeatability in patients with non-small cell lung cancer (NSCLC). To use these statistics to identify which individual target lesions show early biological response.
//
Materials and methods:
A single-centre, prospective DCE-MRI study was performed between September 2015 and April 2017. Patients with NSCLC were scanned before standard-of-care radiotherapy to evaluate biomarker repeatability and two weeks into therapy to evaluate biological response. Volume transfer constant (Ktrans), extravascular extracellular space volume fraction (ve) and plasma volume fraction (vp) were measured at each timepoint along with tumour volume. Repeatability was assessed using a within-subject coefficient of variation (wCV) and repeatability coefficient (RC). Cohort treatment effects on biomarkers were estimated using mixed-effects models. RC limits of agreement revealed which individual target lesions changed beyond that expected with biomarker daily variation.
//
Results:
Fourteen patients (mean age, 67 years +/? 12, 8 men) had 22 evaluable lesions (12 primary tumours, 8 nodal metastases, 2 distant metastases). The wCV (in 8/14 patients) was between 9.16% to 17.02% for all biomarkers except for vp, which was 42.44%. Cohort-level changes were significant for Ktrans and ve (p?<?0.001) and tumour volume (p?=?0.002). Ktrans and tumour volume consistently showed the greatest number of individual lesions showing biological response. In distinction, no individual lesions had a real change in ve despite the cohort-level change.
//
Conclusion:
Identifying individual early biological responders provided additional information to that derived from conventional cohort cohort-level statistics, helping to prioritise which parameters would be best taken forward into future studies.
PB  - SPRINGER
Y1  - 2024/08/09/
A1  - Sridharan, Nivetha
A1  - Salem, Ahmed
A1  - Little, Ross A
A1  - Tariq, Maira
A1  - Cheung, Susan
A1  - Dubec, Michael J
A1  - Faivre-Finn, Corinne
A1  - Parker, Geoffrey JM
A1  - Porta, Nuria
A1  - O'Connor, James PB
ER  -